Alliance Pharma plc (LON:APH)‘s stock had its “buy” rating reissued by investment analysts at FinnCap in a report issued on Thursday. They presently have a GBX 58 ($0.75) price target on the stock. FinnCap’s price target suggests a potential upside of 9.95% from the company’s current price.

APH has been the subject of a number of other research reports. Numis Securities Ltd reaffirmed a “buy” rating and issued a GBX 60 ($0.77) price objective on shares of Alliance Pharma plc in a report on Thursday, May 25th. N+1 Singer reaffirmed a “not rated” rating on shares of Alliance Pharma plc in a report on Wednesday. Finally, Investec initiated coverage on shares of Alliance Pharma plc in a report on Wednesday. They issued a “buy” rating and a GBX 59 ($0.76) price objective for the company.

Alliance Pharma plc (LON:APH) opened at 52.75 on Thursday. Alliance Pharma plc has a 12 month low of GBX 41.33 and a 12 month high of GBX 57.56. The firm’s 50-day moving average is GBX 52.61 and its 200-day moving average is GBX 50.58. The stock’s market cap is GBX 249.36 million.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at

Alliance Pharma plc Company Profile

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.

Receive News & Ratings for Alliance Pharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma plc and related companies with's FREE daily email newsletter.